INTERPACE BIOSCIENCES, INC. (IDXG)

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
06.03.2025	Item 4.02 — Bilanzkorrekturen	EXTREM	SEC	Item 4.02(a). Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed
12.12.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
25.04.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer

Stammdaten

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Unternehmen & Branche

Name	INTERPACE BIOSCIENCES, INC.
Ticker	IDXG
CIK	0001054102
Boerse	US
Sektor	Healthcare
Industrie	Medical - Diagnostics & Research
SIC	3841 · Surgical & Medical Instruments & Apparatus

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	8,8 Mio. USD
Beta	0,97
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	38,728,000	24,575,000	0.89	33,838,000	22,363,000
2025-09-30	10-Q	8,756,000	911,000	0.03	12,036,000	-298,000
2025-06-30	10-Q	9,232,000	-640,000	-0.14	12,335,000	-1,213,000
2025-03-31	10-Q	11,515,000	1,647,000	0.06	14,494,000	-582,000
2024-12-31	10-K	46,926,000	6,702,000	0.40	14,792,000	-2,217,000
2024-09-30	10-Q	12,295,000	1,676,000	0.38	14,039,000	-50,538,000
2024-09-30	10-K	12,295,000	1,676,000	0.38	14,039,000	-50,538,000
2024-06-30	10-Q	12,042,000	2,437,000	0.55	12,972,000	-52,278,000
2024-06-30	10-K	12,042,000	2,437,000	0.55	12,972,000	-52,278,000
2024-03-31	10-K	10,178,000	708,000	0.16	12,142,000	-54,768,000
2024-03-31	10-Q	10,178,000	708,000	0.16	12,142,000	-54,768,000
2023-12-31	10-K	40,036,000	1,954,000	0.45	13,116,000	-55,539,000
2023-09-30	10-K	9,203,000	-186,000	-0.04		-56,724,000
2023-09-30	10-Q	9,078,000	-614,000	-0.14	14,250,000	-62,680,000
2023-06-30	10-Q	11,026,000	175,000	0.04	15,942,000	-62,206,000
2023-06-30	10-K	11,045,000	559,000	0.13	16,063,000	-56,678,000
2023-03-31	10-K	9,655,000	514,000	0.12	15,979,000	-57,394,000
2023-03-31	10-Q	9,826,000	351,000	0.08	15,877,000	-62,538,000
2022-12-31	10-K	5,678,000	-21,958,000	-5.18	15,979,000	-58,091,000
2022-09-30	10-Q	1,267,000	-14,208,000	-3.35	15,293,000	-61,593,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.